http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110787166-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
filingDate | 2019-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2022-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2022-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-110787166-B |
titleOfInvention | Small molecule compound C28H26Cl2N8Application in E.coli meningitis |
abstract | The invention discloses a small molecule compound C 28 H 26 Cl 2 N 8 The compound or an isomer, a solvate or a precursor thereof, or pharmaceutically acceptable salts thereof can be combined with hot spot amino acid residues of interaction of a brain vascular endothelial receptor protein Caspr1 in a bacterial meningitis virulence factor IbeA protein in a targeted competitive manner so as to block the combination of the two, thereby achieving the purpose of preventing the escherichia coli from passing through a blood brain barrier or blocking the meningitis escherichia coli from invading neurons. The invention provides a novel targeted medicine for preventing and treating the bacterial meningitis of the newborn by adopting a novel targeted treatment method from the viewpoints of intervening the interaction of a ligand (IbeA) -receptor (Caspr1) of a bacterium-host and blocking pathogenic bacteria. |
priorityDate | 2019-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.